Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions

Trial Profile

Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Everolimus (Primary) ; Sirolimus (Primary) ; Aspirin; Clopidogrel
  • Indications Coronary artery disease; Coronary artery restenosis; Embolism and thrombosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms EXCELLENT
  • Most Recent Events

    • 16 Dec 2011 Results published in Circulation.
    • 25 Oct 2011 Results published in the Journal of the American College of Cardiology.
    • 21 Sep 2010 Primary non-inferiority endpoint 'In-segment late luminal loss' has been met, according to results presented at the 22nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top